NeonMind to Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic
NeonMind to Improve Patient Care and Data Management by Adopting Digital Platform
for Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health
Clinic
Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and DataCollection
Oakville, Ontario – April 21, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA:6UF) (“NeonMind'' or the “Company”), announced today it has advanced its strategy to streamlineaccess to treatments at its specialty mental health clinics with Thrive Health in preparation of opening itsinaugural clinic located in Mississauga, Ontario.
The recent inclusion of intravenous ketamine for mood and anxiety disorders (IV-Ket) in the Canadianguidelines as a recommended treatment is a testament to the value of this treatment, and a growingnumber of institutions are providing coverage for IV-Ket treatment, setting the precedent for furthercoverage. Using Thrive Health’s robust care management platform to collect patient profiles, managecare programs, and measure treatment outcomes allows us to improve payment coverage for ourtreatments and better serve our patients.
“We are seeing greater institutional coverage for IV-Ket treatment which is a testament to thetreatment’s value to the health system” said Rob Tessarolo, President & CEO of NeonMind. “Institutionalreimbursement validates the treatment in Canada, and we are primed for increased demand for thistreatment”.
Rob Tessarolo also added “NeonMind is focused on improving treatment outcomes and being able tocollect and analyze treatment data throughout our network of clinics will provide a more robust valuestory for adoption of our treatments and establishing payment coverage for our patients. Working withleading digital healthcare platforms such as Thrive Health enables us to deploy our strategies with scale”.
NeonMind will be working with Thrive Health, a trusted digital care platform used by many hospitals andclinics and selected as the official partner by Health Canada in the development of the Canada COVID-19app.
NeonMind's inaugural specialty mental health clinic is located at 89 Queensway West, Suite 604,Mississauga, Ontario, L5B 2V2. For more information related to NeonMind's specialty clinics, pleaseemail [email protected].
About Thrive Health Inc.
Thrive Health was founded in 2016 by a diverse group of patients, clinicians, researchers, parents, andstudents who came together to help patients going through complex health journeys, working to putpeople at the center of their care. Thrive’s platform powers health, wellness and care solutions fororganizations by empowering individuals with compelling digital experiences. Thrive operates acrossNorth America, headquartered in Vancouver BC, and is on a mission to make healthcare work better foreveryone.
For more information about Thrive Health, visit https://welcome.thrive.health/
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development ofpsychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) amedical services division focused on launching specialty mental health clinics that integrate psychedelictherapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programstargeting obesity. NeonMind's lead candidate, NEO-001, employs psilocybin as an agonist at theserotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company'ssecond drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor,which controls appetite.
NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics inCanada that incorporate evidence-backed innovative treatments to address a variety of mental healthneeds. For more information on NeonMind, visit www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this newsrelease.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. Thesestatements relate to future events or NeonMind's future performance. The use of any of the words"could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statementsrelating to matters that are not historical facts are intended to identify forward-looking information andare based on NeonMind's current belief or assumptions as to the outcome and timing of such futureevents. Actual future results may differ materially. In particular, NeonMind's drug development plans, itsability to retain key personnel, and its expectation as to the development of its intellectual property andother steps in its preclinical and clinical drug development constitute forward-looking information. Actualresults and developments may differ materially from those contemplated by forward-lookinginformation. Readers are cautioned not to place undue reliance on forward-looking information. Thestatements made in this press release are made as of the date hereof. NeonMind disclaims any intentionor obligation to publicly update or revise any forward-looking information, whether as a result of newinformation, future events or otherwise, except as may be expressly required by applicable securitieslaws.